Integrating the Use of Calibration-Free Continuous Monitoring for Pregnancy Glucose Profiling: I-Profile Study
Key facts
- Who runs it
- KK Women's and Children's Hospital
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 240 people enrolled
- Started
- 16 Oct 2018
- Ended
- 31 Aug 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Blinded Group
- Unblinded group
- Record updated
- 10 October 2024
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participants who are Singapore citizens or Singapore Permanent Residents, and plan to be followed up throughout pregnancy and intend to deliver at KKH
- Aged 21 and above
- Singleton pregnancy
Who cannot take part
- Have serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days
- Patients who have any other chronic disease such as chronic kidney disease
- Unable to read or speak English
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to test the following hypotheses in a longitudinal, observational study in pregnant women who will be randomized to received either a Blinded or Unblinded CGM sensor and followed-up 6-12 weeks after delivery:
Read full original descriptionShow less
1. CF-CGM device is well tolerable and accurate for glucose level monitoring in women with a normal pregnancy. 2. CF-CGM device is well tolerable and acceptable in women with GDM who are required intensive glucose monitoring on a daily basis during pregnancy and even after delivery. 3. There are trimester-specific glucose profiles observed in the whole pregnancy. 4. Pregnancies complicated with GDM would show a specific glucose profile that is different from non-GDM pregnancies (e.g. greater daily fluctuations, more episodes and longer duration of glucose spikes after meal). 5. There is a good correlation between one-day glucose profile and OGTT test at 24-31 weeks gestation GDM screening. 6. Pre-GDM screening glucose profiles is predictive of GDM diagnosis at 24-31 weeks gestation.
The 2 groups in the trial
- Blinded GroupTreatment being tested
Participants in the blinded group will be wearing the sensor for 14 days without a reader. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
- Unblinded GroupTreatment being tested
Participants in the non-blinded group are required to wear the sensor for 14 days with an open reader. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- First Trimester Mean Glucose Level on Continuous Glucose Monitoring Is Associated with Infant Birth Weight.Diabetes & metabolism journal, 2025
- Record updated
- 10 October 2024